Evidence map›Paper›PMID 41562050›Full record

ArticleFrontiers in immunology2025

Robust neutralization of emerging JN.1 subvariants by the updated JN.1 vaccine: rationale for catch-up booster recommendations in high-risk individuals.

Ju-Yeon Choi, Su-Hwan Kim, Soyoung Park, Hye Min Jang, Young Jae Lee, Hye-Jin Kim, Dokeun Kim, Jae-Hoon Ko, Hye-Sook Jeong

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Ju-Yeon ChoiDivision of Clinical Research for Vaccine, Center for Vaccine Research, National Institute of Infectious Diseases, National Institute of Health, Korea Disease Control and Prevention Agency, Cheongju, Republic of Korea.
Su-Hwan KimDivision of Clinical Research for Vaccine, Center for Vaccine Research, National Institute of Infectious Diseases, National Institute of Health, Korea Disease Control and Prevention Agency, Cheongju, Republic of Korea.
Soyoung ParkDivision of Clinical Research for Vaccine, Center for Vaccine Research, National Institute of Infectious Diseases, National Institute of Health, Korea Disease Control and Prevention Agency, Cheongju, Republic of Korea.
Hye Min JangDivision of Clinical Research for Vaccine, Center for Vaccine Research, National Institute of Infectious Diseases, National Institute of Health, Korea Disease Control and Prevention Agency, Cheongju, Republic of Korea.
Young Jae LeeDivision of Clinical Research for Vaccine, Center for Vaccine Research, National Institute of Infectious Diseases, National Institute of Health, Korea Disease Control and Prevention Agency, Cheongju, Republic of Korea.
Hye-Jin KimDivision of Clinical Research for Vaccine, Center for Vaccine Research, National Institute of Infectious Diseases, National Institute of Health, Korea Disease Control and Prevention Agency, Cheongju, Republic of Korea.
Dokeun KimDivision of Clinical Research for Vaccine, Center for Vaccine Research, National Institute of Infectious Diseases, National Institute of Health, Korea Disease Control and Prevention Agency, Cheongju, Republic of Korea.
Jae-Hoon KoDivision of Infectious Diseases, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
Hye-Sook JeongDivision of Clinical Research for Vaccine, Center for Vaccine Research, National Institute of Infectious Diseases, National Institute of Health, Korea Disease Control and Prevention Agency, Cheongju, Republic of Korea.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The updated JN.1 monovalent vaccine (MoV) for the 2024-2025 season elicits strong cross-neutralizing activity against subsequently circulating SARS-CoV-2 variants in 2025, including the recently emerging NB.1.8.1, with titer increases comparable to those against the vaccine strain JN.1. The immune response induced by the JN.1 MoV was markedly stronger than that induced by XBB.1.5 MoV in the previous season, both against the vaccine strain and post-vaccine variant (all

Indexed as

Antibodies, NeutralizingAntibodies, ViralCOVID-19COVID-19 VaccinesSARS-CoV-2BNT162b5BNT162 VaccineCross ReactionsHumansImmunization, SecondaryAntibodies, NeutralizingAntibodies, ViralBNT162b5BNT162 VaccineCOVID-19 VaccinesCOVID-19cross-reactiveJN.1 subvariantneutralizationSARS-CoV-2

Identifiers

PMID41562050
PMCPMC12812961

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.